A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Annette E. HayNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,

Alli MurugesanDepartment of Biology, University of New Brunswick, Saint John, NB, Canada,

Ashley M. DiPasqualeDepartment of Medicine, Dalhousie University, Saint John, NB, Canada,

Tom KouroukisJuravinski Cancer Centre, Hamilton, ON, Canada,

Irwindeep SandhuDepartment of Medicine, Division of Hematology, University of Alberta, Edmonton, AB, Canada,

Vishal KukretiDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada,

Nizar J. BahlisDivision of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada,

Johan LateganDivision of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada,

Donna E. ReeceDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada,

John F. LyonsAstex Pharmaceuticals, Inc., Dublin, CA, USA, and

Joana SederiasNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,

Hao XuNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,

Jean PowersNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,

Lesley K. SeymourNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,

Tony ReimanDepartment of Biology, University of New Brunswick, Saint John, NB, Canada, ;Department of Oncology, Saint John Regional Hospital and Department of Medicine, Dalhousie University, Saint John, NB, CanadaCorrespondence[email protected]

show all

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date